M&A Deal Summary

Kiora Pharmaceuticals Acquires Panoptes Pharma GES.M.B.H

On December 21, 2020, Kiora Pharmaceuticals acquired life science company Panoptes Pharma GES.M.B.H

Acquisition Highlights
  • This is Kiora Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is Kiora Pharmaceuticals’ 1st transaction in Austria.

M&A Deal Summary

Date 2020-12-21
Target Panoptes Pharma GES.M.B.H
Sector Life Science
Buyer(s) Kiora Pharmaceuticals
Deal Type Add-on Acquisition

Target

Panoptes Pharma GES.M.B.H

Wien, Austria
Panoptes Pharma GES.M.B.H is a clinical stage biotech company focused on developing a novel proprietary small molecule for the treatment of severe eye diseases with a high unmet medical need. Panoptes Pharma was founded in 2013 and is based in Wien, Austria.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Kiora Pharmaceuticals

Encinitas, California, United States

Category Company
Founded 1998
Sector Life Science
Employees12
Revenue 16M USD (2024)
DESCRIPTION

Kiora Pharmaceuticals is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. Kiora Pharmaceuticals was founded in 1998 and is based in Encinitas, California.


DEAL STATS #
Overall 2 of 3
Sector: Life Science M&A 1 of 2
Type: Add-on Acquisition M&A Deals 2 of 3
Country: Austria M&A 1 of 1
Year: 2020 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-03-07 Jade Therapeutics

Salt Lake City, Utah, United States

Jade Therapeutics, Inc. is a provider of locally administered, polymer-based products designed to treat poorly-served ophthalmic indications.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-07-26 Bayon

San Diego, California, United States

Bayon is an ophthalmic specialty pharmaceutical company focused on developing light sensitive small molecules. These photoswitches are specifically designed to restore the eyes’ ability to perceive and interpret vision in visually-impaired patients. Bayon’s lead candidate, a small molecule known as “BENAQ”, selectively enters viable downstream retinal ganglion cells (no longer receiving input from degenerated rods and cones) and turns them into light sensing cells, capable of signaling the brain as to the presence or absence of light. BENAQ, the company’s lead photoswitch, is entering the clinic with an initial focus in patients with later stages of disease progression due to Retinitis Pigmentosa (all sub-forms). Bayon plans to further develop the platform for use in patients with Geographic Atrophy, the later stages of Age-Related Macular Degeneration (dry AMD).

Buy -